Inclusion Criteria:

          1. Capable of giving signed informed consent

          2. Male or female participants ≥ 18 years of age at the time of screening

          3. Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1;
             negative serum or urine pregnancy test on the first day of each subsequent treatment
             period

          4. Participants with any pathologically confirmed solid tumor type for which no standard
             of care therapy exists

          5. Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid
             Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if
             the participant received prior radiation

          6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

          7. Confirmation that an archival tissue sample is available and ≤ 6 months old; if not, a
             new biopsy of a tumor must be obtained

          8. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed
             topical corticosteroids (doses > 10 mg/day prednisone or equivalent) must be
             discontinued at least 2 weeks (14 days) before investigational product administration.
             Physiologic doses of corticosteroids ≤ 10 mg/day of prednisone or its equivalent may
             be permitted

          9. Prior surgery that required general anesthesia or other major surgery as defined by
             the Investigator must be completed at least 4 weeks before investigational product
             administration

         10. Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or
             hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human
             immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening

        12. Adequate organ and marrow function

        Exclusion Criteria:

          1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within
             4 weeks (28 days) of initiation of investigational product

          2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will
             make the administration of investigational product hazardous (eg, interstitial lung
             disease, active infections requiring antibiotics, recent hospitalization with
             unresolved symptoms)

          3. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          4. Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the pre-screening or screening visit
             through 100 days after the last dose of domvanalimab as monotherapy and in combination
             with zimberelimab.

          5. Participants who require a Legally Authorized Representative (LAR) to provide informed
             consent on their behalf.

          6. Any active autoimmune disease or a documented history of autoimmune disease or history
             of a syndrome that required systemic steroids or immunosuppressive medications, except
             for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require
             intermittent use of bronchodilators (such as albuterol) will not be excluded from this
             study

          7. Prior malignancy active within the previous year except for locally curable cancers
             that have been apparently cured, such as basal or squamous cell skin cancer,
             superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate
             cancer

          8. Has had prior chemotherapy, targeted small-molecule therapy, immunotherapy (tumor
             vaccine, cytokine, or growth factor given to control the cancer), biologic agents or
             radiation therapy within 4 weeks (or 5 half-lives) prior to Day 1 or has not recovered
             from AEs due to a previously administered agent

          9. Use of other investigational drugs within 28 days or at least 5 half-lives before
             investigational product administration.